Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTSVJM)

Drug Name
CJM112 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Phase 2 [1]
Chronic plaque psoriasis EA90.0 Phase 1/2 [2]
Multiple myeloma 2A83 Phase 1 [3]
Plaque psoriasis EA90.0 Phase 1 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Cross-matching ID
TTD Drug ID
DMTSVJM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-17 (IL17) DTT IL17A 5.188 3.828 3.329 4.615
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02998671) Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)